Biogen Shifts Strategy Beyond Neurology With 10 Phase III Readouts on the Horizon
Biogen is expanding its clinical and commercial focus into nephrology and immunology through recent acquisitions, aiming to stabilize revenue as legacy multiple sclerosis sales contract.


